"Cabaletta Bio Shares Promising Data on Rese-cel for Autoimmune Diseases "

Cabaletta Bio has unveiled new clinical data on rese-cel, a groundbreaking cell therapy aimed at treating autoimmune diseases without the need for steroids or immunosuppressants. Presented at major scientific conferences in the U.S. and Germany, the findings highlight promising responses across multiple trials. Patients with lupus, myositis, and systemic sclerosis have shown significant improvement, including remission in systemic lupus erythematosus (SLE) and major progress in dermatomyositis. With a rapid enrollment rate and strong early results, Cabaletta plans to discuss registrational trial designs with the FDA in 2025.

The RESET program, which includes six Phase 1/2 clinical trials, evaluates rese-cel’s potential across rheumatology, neurology, and dermatology. Unlike conventional treatments, rese-cel is designed as a one-time infusion following a preconditioning regimen, except in the RESET-PV™ trial, which omits preconditioning. With an expanding network of clinical sites in the U.S. and Europe, Cabaletta is accelerating patient enrollment and expects to gather crucial data this year. If successful, rese-cel could revolutionize autoimmune disease treatment, offering long-term benefits without the burden of chronic immunosuppressive therapy.